Third-generation Audi Q3 unveiled, gets hybrid powertrains
Audi has taken the wraps off the all-new Q3, the third generation of its premium compact SUV. With over two million units sold globally since its debut, the Q3 remains a cornerstone of Audi's lineup. The latest iteration elevates the formula with mild-hybrid and plug-in hybrid powertrains.
advertisementDesignThe 2025 Audi Q3 sports a more muscular, emotive exterior, featuring a wide Singleframe grille, sleek LED headlights, and a dynamic shoulder line that accentuates its silhouette. Aerodynamic refinements—including an optimised cool-air intake—help achieve a drag coefficient of 0.30. For the first time in the compact segment, Audi offers digital OLED taillights and acoustic glazing for quieter cabin refinement.
Digital Matrix LED headlights debut micro-LED tech
Audi's lighting prowess shines with digital Matrix LED headlights featuring micro-LED technology—a segment first. The system employs 25,600 micro-LEDs per module (each half the width of a human hair) for sharper illumination and adaptive functions. The lights integrate with driver-assist systems, projecting warnings (like icy road alerts) onto the road and adjusting beam patterns for construction zones.Interior
advertisement
Inside, the Q3 adopts Audi's 'digital stage' concept, featuring an 11.9-inch digital cockpit and 12.8-inch MMI touchscreen running Android Automotive OS. The AI-powered Audi Assistant debuts as an interactive avatar, responding to voice commands. A redesigned steering wheel frees up console space by relocating gear selection.Recycled materials dominate upholstery, including fabrics made from polyester and Econyl (recycled nylon from fishing nets). The optional Sonos premium sound system delivers 420W of immersive audio.
Mild-Hybrid and PHEV PowertrainsThe Q3 lineup includes:TFSI 1.5L mild-hybrid (150bhp) with cylinder deactivation.TDI diesel (150bhp) for long-distance efficiency.Plug-in hybrid (Q3 e-hybrid) with 200kW (272bhp) and a 119km electric range (WLTP preliminary). The PHEV supports 50kW DC fast charging, reaching 80% in under 30 minutes.SafetyAudi revamped the suspension with optional adaptive dampers and progressive steering for sharper handling. Driver aids include:Adaptive cruise assist with lane-change support (up to 210 km/h).Emergency assist (auto-pulls over if driver is unresponsive).Trained Parking (memorises custom manoeuvres).Digital rearview mirror and 360 cameras.Pricing and availabilityInternationally, orders will open in summer 2025, with deliveries scheduled to begin in October. German pricing starts at:Subscribe to Auto Today Magazine44,600 - Q3 TFSI mild-hybrid (Approx. Rs 44.23 lakh)49,300 - Q3 e-hybrid PHEV (Approx. Rs 48.88 lakh).
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
22 minutes ago
- Hans India
India pharma market grows 6.9 pc in May, chronic therapies lead
New Delhi: The India pharma market (IPM) grew 6.9 per cent (on-year) in May, driven by strong outperformance in cardiac, respiratory, and anti-diabetes therapies, a report showed on Tuesday. In May, Indian companies grew 6.6 per cent, while MNCs grew 8.4 per cent YoY. Acute therapy growth stood at 5 per cent in May, the second consecutive month of muted YoY growth, according to the report by Motilal Oswal Financial Services Ltd. For the 12 months ending in May, IPM growth was led by price/new launches/volume growth of 4.2 per cent/2.3 per cent/1.1 per cent YoY. As of May, the Indian pharma companies held a majority share of 83 per cent in IPM, with the remaining held by multi-national pharma companies (MNCs). In May, among the top 20 pharma companies, JB Chem (up 11.6 per cent YoY), Glenmark (up 11.8 per cent YoY), and Ajanta (up 10.6 per cent YoY) recorded higher growth rates vs IPM. Ajanta outperformed IPM, led by strong double-digit growth across key therapies like Anti Diabetic/Ophthal. JB Chemicals outperformed IPM, led by a strong show in Cardiac/Ophthal/Anti Parasitic. On a MAT basis, the industry reported 7.6 per cent YoY growth. Chronic therapies witnessed 10 per cent YoY growth, while acute therapies displayed 5 per cent YoY growth in May, said the report. Meanwhile, India's pharmaceutical industry, which has emerged as the largest supplier of affordable generic medicines, is poised to grow at 7.8 per cent year-on-year in April 2025 driven by strong demand and new products, according to experts at India Ratings. The country's pharma sector is now ranked 3rd in volume and 14th in value globally and contributes as much as 20 per cent of the world's supply of medicines. The turnover of the Indian pharma industry touched Rs 4,17,345 crore in 2023-24 growing steadily at over 10 per cent annually for the past five years.
News18
26 minutes ago
- News18
Bollywood Actor Jaideep Ahlawat Buys Another Rs 10 Crore Flat With Wife Jyoti Hooda in Mumbai
Last Updated: Actor Jaideep Ahlawat and his wife Jyoti Hooda bought two apartments in Poorna Apartments, Andheri West, each priced at Rs 10 crore. A month after buying an apartment in Andheri West, actor Jaideep Ahlawat and his wife Jyoti Hooda have purchased another apartment in the same Poorna Apartments (Andheri West), on a different floor. The couple bought the first apartment in May 2025 and the second one in June. Each apartment is priced at Rs 10 crore each, according to property registration documents reviewed by Square Yards. The latest transaction was registered in June 2025. This is the couple's second purchase in the same residential project — Poorna Apartments — within a span of two months. The first apartment was bought in May 2025 for the same value and is located on a different floor in the same residential project. Both apartments have similar configurations and areas. According to the IGR property registration documents reviewed by Square Yards, the value of latest purchased apartment in June 2025 stands at Rs 10 crore. It has a carpet area of 1,950 sqft (nearly 181 sqm) and a built-up area of 217.47 sqm (nearly 2,341 sqft), which is the same as the apartment acquired in May. The deal also includes two car parking spaces. The transaction attracted a stamp duty payment of Rs 60 lakh and registration charges of Rs 30,000. Details of the Previous Transaction Registered in May 2025 According to the IGR property registration documents reviewed by Square Yards, the property purchased in May 2025, also for Rs 10 crore, features a similar carpet area of 1,950 sqft (nearly 181 sqm) and a built-up area of 217.47 sqm (nearly 2,341 sqft). It included a total of four car parking spaces. The transaction incurred a stamp duty payment of Rs 60 lakh and registration charges of Rs 30,000. Strategically positioned between Mumbai's prominent business districts and entertainment zones, Andheri West boasts excellent connectivity through the Western Express Highway, Link Road, SV Road, and the Versova-Andheri-Ghatkopar Metro line. Over the years, Andheri West has evolved into a dynamic commercial and residential destination, featuring a lively blend of modern office complexes, co-working spaces, upscale retail outlets, entertainment centres, and premium residential developments. The area's vibrant atmosphere, coupled with its robust infrastructure and proximity to key commercial hubs, makes it a preferred choice for businesses, celebrities and working professionals. Jaideep Ahlawat is an Indian actor who works in Hindi films and web series. He gained recognition for his roles in the films Raees (2017) and Raazi (2018). In 2020, he starred as a police officer in the streaming series Paatal Lok, for which he received the Filmfare OTT Award for Best Actor in a Drama Series. Most recently, he appeared alongside Saif Ali Khan in the Netflix film Jewel Thief (2025).
Time of India
31 minutes ago
- Time of India
ArisInfra Solutions shares GMP at 11% in unlisted market. Check IPO details
Shares of the tech-driven B2B construction materials platform ArisInfra Solutions are trading at a grey market premium of 10.8% or Rs 24-25 in the unlisted market ahead of the opening of its initial public offering (IPO) on June 18. The GMP refers to the premium at which shares of an upcoming IPO are trading in the unofficial or grey market before they are listed on the stock exchange. A high or positive GMP suggests strong investor demand and that the stock is likely to list at a price above its issue price. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 21st Century Skills Start with Confident Communication Planet Spark Learn More Undo A negative or zero GMP indicates weak demand and the possibility of a discount listing. However, one should note that GMP is not regulated by SEBI or stock exchanges and is driven by market sentiment and may not always reflect the actual listing price. It is often used by retail and HNI investors to gauge possible listing gains or losses. About ArisInfra Solutions IPO Live Events The IPO, comprising solely a fresh issue of equity shares, and has set a price band of Rs 210–222 per share for its Rs 500 crore IPO, which will open for subscription on June 18 and close on June 20. The shares of the company are expected to be listed on BSE and NSE on June 25. Allotment is likely to be finalized by June 23. As per the minimum bid details, retail investors are required to apply for at least one lot comprising 67 shares, amounting to an investment of Rs 14,070 at the lower price band or Rs 14,874 at the upper band to be eligible for allotment. For sNII investors, the minimum application is 14 lots (938 shares), requiring an investment of approximately Rs 2,08,236, while the NIIs must bid for a minimum of 68 lots (4,556 shares), amounting to Rs 10,11,432. As stated in the company's Draft Red Herring Prospectus (DRHP), the net proceeds from the public issue will primarily be utilized to meet ArisInfra's working capital requirements as it expands its operations across various regions. The issue is being managed by JM Financial , IIFL Capital Services , and Nuvama Wealth Management , while MUFG Intime India (Link Intime) has been appointed as the registrar to the offer. About ArisInfra Solutions Founded in 2021, ArisInfra Solutions is backed by Siddharth Shah, co-founder of PharmEasy, and is focused on digitally transforming the procurement ecosystem for construction materials. The company operates as a technology-driven B2B procurement platform, serving institutional buyers such as real estate developers, contractors, and infrastructure companies with bulk materials like steel, cement, and aggregates. ArisInfra integrates warehousing, logistics, quality control, and just-in-time delivery into a unified digital platform. Through its streamlined interface, clients can seamlessly place orders, track shipments, manage documentation, and access technical support — positioning the company at the forefront of innovation in the construction supply chain sector. ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
